151 related articles for article (PubMed ID: 38012985)
1. Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges.
O'Leary CL; Pierce N; Patel SP; Naidoo J
J Thorac Oncol; 2024 Mar; 19(3):395-408. PubMed ID: 38012985
[TBL] [Abstract][Full Text] [Related]
2. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
[TBL] [Abstract][Full Text] [Related]
3. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
5. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS
Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771
[TBL] [Abstract][Full Text] [Related]
6. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K; Naidoo J; Lin CT; Danoff S
Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
[TBL] [Abstract][Full Text] [Related]
8. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
Zhou L; Wei X
Front Immunol; 2021; 12():701951. PubMed ID: 34504488
[TBL] [Abstract][Full Text] [Related]
9. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.
Owen DH; Wei L; Bertino EM; Edd T; Villalona-Calero MA; He K; Shields PG; Carbone DP; Otterson GA
Clin Lung Cancer; 2018 Nov; 19(6):e893-e900. PubMed ID: 30197259
[TBL] [Abstract][Full Text] [Related]
10. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors.
Hu X; Wang L; Shang B; Wang J; Sun J; Liang B; Su L; You W; Jiang S
Front Immunol; 2023; 14():1094414. PubMed ID: 36949956
[TBL] [Abstract][Full Text] [Related]
12. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.
Xu H; Feng H; Zhang W; Wei F; Zhou L; Liu L; Zhao Y; Lv Y; Shi X; Zhang J; Ren X
Exp Cell Res; 2022 Jul; 416(1):113157. PubMed ID: 35427598
[TBL] [Abstract][Full Text] [Related]
13. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
Cathcart-Rake EJ; Sangaralingham LR; Henk HJ; Shah ND; Riaz IB; Mansfield AS
Clin Lung Cancer; 2020 Sep; 21(5):421-427.e2. PubMed ID: 32446852
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
[TBL] [Abstract][Full Text] [Related]
15. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
16. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
Naidoo J; Nishino M; Patel SP; Shankar B; Rekhtman N; Illei P; Camus P
Clin Lung Cancer; 2020 Sep; 21(5):e435-e444. PubMed ID: 32576443
[TBL] [Abstract][Full Text] [Related]
17. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
[TBL] [Abstract][Full Text] [Related]
18. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
Barron CC; Stefanova I; Cha Y; Elsolh K; Zereshkian A; Gaafour N; McWhirter E
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536939
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events.
Kujtan L; Kancha RK; Gustafson B; Douglass L; Ward CR; Buzard B; Subramanian J
Expert Rev Anticancer Ther; 2022 Feb; 22(2):203-213. PubMed ID: 35034561
[TBL] [Abstract][Full Text] [Related]
20. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]